Press Releases

Emergent BioSolutions Receives FDA Approval for BioThrax Supplemental Biologics License Application

...

Read More

Emergent BioSolutions to Webcast Presentation at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009

...

Read More

Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on November 20, 2008

...

Read More

Emergent BioSolutions Files Universal Shelf Registration Statement

...

Read More

Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008

...

Read More

Emergent BioSolutions to Webcast Presentation at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008

...

Read More

Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008

...

Read More

U.S. Government Issues Declaration Covering Emergent BioSolutions’ BioThrax(R) and Anthrax Immune Globulin under Prep Act

...

Read More

U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million

...

Read More

Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 – A Next Generation Anthrax Vaccine

...

Read More

Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range

...

Read More

Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody

...

Read More